- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, November 30, 2018
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Several articles from The American Journal of Managed Care®’s The Center for Biosimilars® were included in newsletters this week.
The National Pharmaceutical Council (NPC)’s Monday CER Daily Newsfeed included the article, “UK Providers Seek More Real-World Evidence, Financial Incentives for Biosimilar Use,” which covered a study that assessed attitudes toward biosimilars in the clinical specialties of diabetes, inflammatory bowel disease, and rheumatology. Tuesday’s CER Daily Newsfeed included the article, “Pharma to Cap UK Sales Growth in Exchange for Faster NICE Appraisals and Launches,” which reported that the Association of the British Pharmaceutical Industry announced a voluntary deal with the UK government that involves capping the growth of sales of drugs to the National Health Service at 2% per year in exchange for faster product launches and speedier appraisals.
OBR Oncology’s Tuesday daily newsfeed mentioned the article “New CMS Proposal Includes Prior Authorizations and Step Therapy for Part D Dugs,” which reported on the proposed rule that would allow Part D sponsors to exclude drugs from formulary if they represent only new formulations of existing single-source drugs or biologics, as well as exclude drugs if their prices exceed a certain threshold over a specific look-back period. The rule also allows plans to make broader use of prior authorization and step therapy for drugs covered under Part D. Their Wednesday daily newsfeed included the article “FDA Approves Celltrion’s Rituximab Biosimilar, Truxima,” which covered the FDA’s approval of the biosimilar, referencing Rituxan, for the treatment of adults with CD20-positive, B-cell non-Hodgkin lymphoma either as monotherapy or in combination with chemotherapy.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
